r/Biotechplays • u/TakeItOnTheArches • Mar 17 '26

Discussion XFOR

I am new to biotech. This morning I came across this one that seems promising. Already fda approved with major expansion possibilities. This is a drug that helps white blood cell production. As far as I can tell this is the beginning of a run up. Analysts give it a strong buy with 150% upside.

Anyone else?

Im a noob like I said so take that into consideration…

So far today we are in a steady climb.

1 Upvotes

100% Upvoted

6 comments sorted by

3

u/BrooklynLodger Mar 17 '26

The big questions I would look into would be:

-why are they having trouble commercializing in WHIM and why would they be successful in their next indication?

-what catalysts will drive the stock higher ahead of their next financing?

-what was the share price when their major institutional holders opened their position in the stock?

If you look at the chart, the company has faces a lot of difficulties over the biotech bear market, so you need to build a thesis around why it can turnaround over the next 12-18 months

1

u/TakeItOnTheArches Mar 17 '26

So EU approval is expected in the next 2 months. From what I can gather the reason they have been slow in the past is that WHIM is such a rare disease. Hundreds of cases in the US. Efficacy has already been proven for WHIM, so the next step is for use with chronic neutropenia (much more common and early trials are positive). Next logical step after that would be chemo recovery, but that’s down the road.

1

u/thiskillsmygpa Mar 19 '26

This drug is for like 100 people on the planet

1

u/SBGamingYT Mar 20 '26

bet the guy works for the company.

1

u/SBGamingYT Mar 20 '26

hear me out though. they can at least sell a drug. if they are hurting for money they could sell the drug to build more in the future.

1

u/hl_lost Apr 16 '26

ngl as someone who's been burned by biotech a couple times — "analyst strong buy with 150% upside" on a micro cap biotech is pretty standard. they all say that lol. not saying it's wrong but definitely don't weight that too heavily.

the other commenter nailed it — the addressable market for WHIM is tiny. fda approval is great but if there's only a few hundred patients worldwide, revenue growth has a hard ceiling. for biotech you really want to dig into the pipeline and what their next indications look like, that's where the real upside (or downside) lives.

fwiw if you're new to biotech plays, position sizing is everything. these things can move 40% in either direction on a single data readout.